Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

Maria Shriver, Ann O’Leary introduce The Shriver Report for Alzheimer's patients

Guests Maria Shriver (First Lady-California) and Ann O'Leary (Berkeley Center for Health, Economic and Family Security) appeared yesterday to introduce The Shriver Report: A Woman's Nation takes on Alzheimer's on the ABC Sunday morning show This Week with Christiane Amanpour

19 Oct 2010

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

The US Department of Defense (DOD) has awarded a $5 million grant to The Feinstein Institute for Medical Research and the University of Cincinnati to further develop a "lab-on-a-chip" device used for monitoring patients suffering from severe brain injury.

19 Oct 2010

New ADNI-GO effort enables researchers to study Alzheimer's disease

Volunteers in New York, NY are being sought for a clinical study examining the subtle changes that may take place in the brains of older people many years before overt symptoms of Alzheimer's disease (AD) appear. Researchers at Columbia University Medical Center are specifically looking for people with the very earliest complaints of memory problems that affect their daily activities. The study will follow participants over time, using imaging techniques specifically developed to advance research into changes taking place in the structure and function of the living brain, as well as biomarker measures found in blood and cerebrospinal fluid.

19 Oct 2010

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Finding a drug that can cross the blood-brain barrier is the bane of drug development for Alzheimer's disease and other neurological disorders of the brain. A new Penn study, published this week in the Journal of Neuroscience, has found and tested in an animal model of Alzheimer's disease a class of drug that is able to enter the brain, where it stabilizes degenerating neurons and improves memory and learning.

19 Oct 2010

biOasis receives final report on Collaborative Research project from UBC

biOasis Technologies Inc. has received a final report detailing results achieved within the Collaborative Research project with The University of British Columbia (UBC) that was announced by the Company on June 2, 2009.

19 Oct 2010

Vitamin B12 may help protect against Alzheimer's disease

A new study shows that vitamin B12 may protect against Alzheimer's disease, adding more evidence to the scientific debate about whether the vitamin is effective in reducing the risk of memory loss. The research will be published in the October 19, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

19 Oct 2010

UCSF professor receives National Medal of Science

UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.

18 Oct 2010

UT Dallas researcher receives NIH grant

For the second time this year, a postdoctoral fellow in UT Dallas' Center for Vital Longevity has earned a prestigious, highly competitive career-development grant from the National Institutes of Health (NIH).

18 Oct 2010

Major advance in treatment of brain disorders with external genes

In the October 17 issue of Nature Methods, researchers at Thomas Jefferson University describe how they can transfer genes into brain neurons intravenously, using a viral gene delivery vehicle (vector) that causes no side effects.

18 Oct 2010

Researchers identify new paradigm for regulation of alternative splicing

How a T cell decides to make protein X, Y, or Z can have profound effects for fighting foreign invaders or staving off dire autoimmune reactions. Researchers at the University of Pennsylvania School of Medicine have identified the steps that control how different forms of an immune cell protein called CD45, which is critical for activating the immune system when faced with pathogens, are controlled in the arc of a body's immune response.

18 Oct 2010

Shrink reveals image of StemDisc450 biomedical research tool

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.

18 Oct 2010

Scientists find unexpected function of cell's protein-making machinery

When cells make the proteins that carry out virtually every function of life, it's vital that the right things happen at the right times, and maybe more importantly that wrong things are stopped from happening at the wrong times.

18 Oct 2010

Diagnosis is vital to differentiae Lewy body dementia and Parkinson's disease dementia

Alzheimer's disease is not the only type of dementia. Two particular forms are dementia with Lewy bodies and Parkinson's disease dementia. In both forms, the diagnosis is of vital importance because the treatment for these dementias differs from that for Alzheimer's dementia, as Brit Mollenhauer and co-authors explain in the dementia theme issue of Deutsches -rzteblatt International.

18 Oct 2010

Few Americans plan for Alzheimer's despite rise in awareness

A growing number of Americans report knowing a relative or friend afflicted with Alzheimer's, according to a national poll conducted by the public opinion research firm Abt SRBI. Yet despite this rise in awareness, often accompanied by significant anxiety about one day getting this fatal brain disease, few Americans are planning for its eventuality.

15 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

FDA warns companies over unsubstantiated claims of 'chelation' products

The Food and Drug Administration says there's no proof that nonprescription 'chelation' products—which claim to treat everything from autism to Alzheimer's disease—can rid the body of toxic metals.

15 Oct 2010

The Shriver Report reveals AD’s epidemic effect on women

Maria Shriver and the Alzheimer's Association the leader in Alzheimer's care, support and research today released The Shriver Report: A Woman's Nation Takes on Alzheimer's. This groundbreaking report reveals the epidemic's effect on women as caregivers, advocates and people living with this disease.

14 Oct 2010

EFNS recommends use of DaTSCAN injection with SPECT imaging for AD diagnosis

GE Healthcare, a unit of General Electric Company, today announced that DaTSCAN (ioflupane I 123 injection), a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging of the brain, has been recommended in updated European Federation of the Neurological Societies (EFNS) guidelines for the diagnosis and management of Alzheimer's disease (AD). The guidelines appear in the October issue of the European Journal of Neurology.

14 Oct 2010